P Vivax management
Reading File
Finding Sources
Finding Sources
Searching PubMed
"Plasmodium vivax" AND treatment
Reading File
Reading File
Reading File
Reading File
Reading File
I now have comprehensive content from multiple authoritative sources. Let me compile the full answer:
Management of Plasmodium vivax Malaria
Overview
P. vivax is the most geographically widespread malaria species. Unlike P. falciparum, it forms hypnozoites - dormant liver-stage parasites responsible for relapses weeks to months after the initial infection. Management therefore has two distinct goals: treating the acute blood-stage illness and radical cure (eradicating hypnozoites to prevent relapse).
1. Diagnosis
Confirmed by:
- RDT (Bivalent) or
- Peripheral blood smear (thick/thin film microscopy)
Always check for concurrent P. falciparum co-infection, as dual infections are possible.
2. Uncomplicated P. vivax Malaria
A. Chloroquine-Sensitive Areas (Most Regions)
Step 1 - Chloroquine (blood schizonticide):
- 25 mg/kg total over 3 days
- Day 1: 10 mg/kg
- Day 2: 10 mg/kg
- Day 3: 5 mg/kg
Step 2 - Primaquine (anti-hypnozoite / radical cure):
- 0.25 mg/kg/day for 14 days
- Adult dose (≥15 years): 30 mg base/day for 14 days (6 tablets of 2.5 mg each)
- Must be given under supervision
- Check G6PD status before starting - hemolysis risk in G6PD-deficient individuals
Dosage Chart (India NVBDCP / Park's):
| Age | CQ (150 mg base) Day 1 | CQ Day 2 | CQ Day 3 | PQ (2.5 mg) Days 1-14 |
|---|---|---|---|---|
| <1 year | ½ tab | ½ tab | ¼ tab | Nil |
| 1-4 years | 1 tab | 1 tab | ½ tab | 1 tab |
| 5-8 years | 2 tabs | 2 tabs | 1 tab | 2 tabs |
| 9-14 years | 3 tabs | 3 tabs | 1½ tabs | 4 tabs |
| ≥15 years | 4 tabs | 4 tabs | 2 tabs | 6 tabs |
| Pregnancy | 4 tabs | 4 tabs | 2 tabs | Nil |
(Park's Textbook of Preventive and Social Medicine)
B. Chloroquine-Resistant Areas
Chloroquine resistance in P. vivax is well documented in parts of Southeast Asia (especially Papua New Guinea, Indonesia, Papua province), Oceania, and some parts of South America.
Use Artemisinin-Based Combination Therapy (ACT):
- Artemether-lumefantrine (AL) - fixed dose combination, preferred
- Artesunate + mefloquine, or artesunate + amodiaquine
- Follow with primaquine for radical cure (same 14-day regimen) once G6PD status confirmed
(Goldman-Cecil Medicine; Tintinalli's Emergency Medicine)
3. Radical Cure - Anti-Hypnozoite Therapy
This is the defining feature of vivax management. Without it, relapses occur in 50-80% of cases.
Primaquine
- Standard dose: 0.25 mg/kg/day for 14 days (total 3.5 mg/kg)
- For high-relapse strains (SE Asia, Oceania): 0.5 mg/kg/day for 14 days
- Most effective when started before completion of chloroquine dosing
Tafenoquine (newer option, single-dose)
- Single dose: 300 mg (FDA approved 2018)
- Advantage: single-dose improves adherence
- Same contraindications as primaquine (G6PD deficiency, pregnancy)
- Requires G6PD testing before use
Special Considerations:
- Needlestick / transfusion-acquired vivax: No primaquine needed (no liver hypnozoites)
- G6PD-deficient patients: Avoid primaquine/tafenoquine; use chloroquine 300 mg weekly for 6 months as an alternative (suppressive therapy)
- Pregnancy: Primaquine is contraindicated; give chloroquine weekly until delivery, then complete radical cure postpartum
- Infants (<1 year): Primaquine is contraindicated
(Katzung's Basic and Clinical Pharmacology, 16th Ed; Tintinalli's Emergency Medicine)
4. Severe/Complicated P. vivax Malaria
Though rare (mostly a falciparum scenario), severe vivax does occur. Manage similarly to severe falciparum:
Parenteral therapy:
- IV Artesunate (WHO preferred): 2.4 mg/kg IV at 0, 8, and 24 hours, then daily
- IV Quinine gluconate (alternative): 6.25 mg base/kg over 2 hours, then 0.0125 mg base/kg/min continuous infusion (with IV doxycycline or clindamycin)
Switch to oral therapy as soon as patient can tolerate it; complete a full course. Add primaquine after recovery for radical cure.
(Tintinalli's Emergency Medicine, Table 159-3)
5. Chemoprophylaxis
| Regimen | Dose |
|---|---|
| Chloroquine (sensitive areas only) | 300 mg base weekly |
| Primaquine (causal prophylaxis) | 30 mg base daily |
| Tafenoquine | 200 mg daily x3 days loading, then 200 mg weekly |
| Atovaquone-proguanil | 250/100 mg daily |
Note: Standard blood-stage schizonticide prophylaxis does not prevent relapse. Terminal prophylaxis with primaquine is recommended after leaving endemic areas for P. vivax.
6. Key Contraindications Summary
| Drug | Contraindications |
|---|---|
| Primaquine | G6PD deficiency, pregnancy, infants <1 year |
| Tafenoquine | G6PD deficiency, pregnancy, breastfeeding (infant G6PD unknown) |
| Chloroquine | Retinal/macular disease (long-term use) |
7. Recent Evidence (2024-2026)
- A 2024-2025 IPD meta-analysis (PMID 41239453) confirmed primaquine dose-efficacy relationships; higher doses (0.5 mg/kg/day) needed for Southeast Asian strains with higher relapse rates.
- PMID 39331646 (PLoS Med 2024) validated methemoglobin as a surrogate marker of primaquine anti-hypnozoite activity - useful for monitoring therapeutic adequacy.
- PMID 41261454 (2025) evaluated point-of-care G6PD biosensors, supporting practical pre-treatment G6PD screening before primaquine/tafenoquine.
- CYP2D6 polymorphisms (affecting primaquine metabolism) are emerging as a cause of treatment failure in some populations (PMID 41187952, 2026).
Sources: Park's Textbook of Preventive and Social Medicine | Katzung's Basic and Clinical Pharmacology, 16th Ed | Tintinalli's Emergency Medicine | Goldman-Cecil Medicine
This is a shared conversation. Sign in to Orris to start your own chat.